This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Bristol Myers' (BMY) NDA for Mavacamten Accepted by FDA
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) new drug application for mavacamten for treating patients with symptomatic obstructive hypertrophic cardiomyopathy.
BMYPositive Net Change RGENPositive Net Change NBRVPositive Net Change CTMXNegative Net Change
biotechs
J&J's (JNJ) Multiple Sclerosis Drug Ponesimod Gets FDA Nod
by Zacks Equity Research
J&J's (JNJ) ponesimod demonstrated superior clinical efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.
JNJPositive Net Change SNYNegative Net Change NVSPositive Net Change BMYPositive Net Change
biotechs
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Delay in FDA approval for latest COVID test hasn't altered growth or value at 3X sales
VIVONegative Net Change HOLXPositive Net Change NVAXPositive Net Change QDELPositive Net Change
biotechs coronavirus medical
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk
by Zacks Equity Research
Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.
NVOPositive Net Change GILDNegative Net Change VKTXNegative Net Change ICPTPositive Net Change
biotechs pharmaceuticals
Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC
by Zacks Equity Research
Exelixis (EXEL) signs a collaboration and supply agreement with Merck KGaA and Pfizer to investigate XL092 in combination with Bavencio for treating various forms of urothelial carcinoma.
RHHBYPositive Net Change PFEPositive Net Change EXELPositive Net Change RGENPositive Net Change
biotechs
Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.
ILMNPositive Net Change HOLXPositive Net Change ABTPositive Net Change IDXXNegative Net Change
biotechs medical
Cytokinetics (CYTK) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Cytokinetics (CYTK) has moved higher as of late, but there could definitely be trouble on the horizon for this company
CYTKNegative Net Change
biotechs medical
Moderna (MRNA) Begins Pediatric Study on COVID-19 Vaccine
by Zacks Equity Research
Moderna is developing its COVID-19 vaccine, mRNA-1273, for different patient populations. It is also developing booster vaccine candidates as well as a next-generation COVID vaccine.
JNJPositive Net Change AZNPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
REGNPositive Net Change SNYNegative Net Change GILDNegative Net Change NVAXPositive Net Change TBIONegative Net Change
biotechs medical
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
REGNPositive Net Change SNYNegative Net Change GILDNegative Net Change GSKPositive Net Change NVAXPositive Net Change TBIONegative Net Change VIRPositive Net Change
biotechs pharmaceuticals
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
HOLXPositive Net Change QGENPositive Net Change IDXXNegative Net Change INOPositive Net Change
biotechs medical
Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments
by Zacks Equity Research
Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.
GILDNegative Net Change MRKNegative Net Change MRNAPositive Net Change GSKPositive Net Change
biotechs pharmaceuticals
Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down
by Zacks Equity Research
Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.
PFEPositive Net Change SRPTPositive Net Change WVENegative Net Change SLDBNegative Net Change
biotechs
AVEO Collaborates with Bristol Myers to Conduct Combo Study
by Zacks Equity Research
AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.
MRKNegative Net Change EXELPositive Net Change BMYPositive Net Change AVEOPositive Net Change
biotechs pharmaceuticals
Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi announce favorable data on their oncology drug Libtayo from a phase III study on cervical cancer.
REGNPositive Net Change SNYNegative Net Change MRNAPositive Net Change BAYRYNegative Net Change
biotechs pharmaceuticals
Leveraged ETFs In the Pink After 1 Year of Pandemic
by Sweta Killa
Investors flocked to leveraged ETFs to cash in on the opportunity offered by an improving economy and a rising stock market.
LABUNegative Net Change SOXLNegative Net Change URTYNegative Net Change RETLNo Net Change TPORNegative Net Change FNGUNegative Net Change UBOTNegative Net Change WEBLNegative Net Change HIBLNegative Net Change
biotechs etfs fang internet marijuana retail semiconductor transportation
Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves to be 96.4% effective in final analysis in the phase III study in the United Kingdom. Shares up.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs
Moving Average Crossover Alert: Seagen
by Zacks Equity Research
Seagen (SGEN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
SGENPositive Net Change
biotechs
Novavax ETFs to Shine Bright on Positive Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development and distribution amid the pandemic.
JNJPositive Net Change NVAXPositive Net Change IBBNegative Net Change XBINegative Net Change BBHPositive Net Change
biotechs etfs
Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails
by Zacks Equity Research
Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.
REGNPositive Net Change RHHBYPositive Net Change GILDNegative Net Change LLYPositive Net Change
biotechs pharmaceuticals
Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk
by Zacks Equity Research
Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.
INCYPositive Net Change LLYPositive Net Change GSKPositive Net Change VIRPositive Net Change
biotechs
bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study
by Zacks Equity Research
bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.
VRTXPositive Net Change EDITNegative Net Change CRSPNegative Net Change
biotechs
Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins
by Zacks Equity Research
Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.
ACORPositive Net Change MRNAPositive Net Change VRTXPositive Net Change CRSPNegative Net Change
biotechs
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
GILDNegative Net Change AMGNPositive Net Change FPRXPositive Net Change ACADPositive Net Change IMVTNegative Net Change
biotechs pharmaceuticals
BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.
MRNAPositive Net Change BDSIPositive Net Change CTMXNegative Net Change ASLNNegative Net Change
biotechs earnings